A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. - Wikidata - awgldk - TriplyDB

A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer.

A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer.

http://www.wikidata.org/entity/Q40405703

about

Systemic delivery of oncolytic viruses: hopes and hurdles New viruses for cancer therapy: meeting clinical needs Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2 Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants Going viral: a review of replication-selective oncolytic adenoviruses Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics.Oncolytic virotherapy for pediatric malignancies: future prospects Trial Watch-Oncolytic viruses and cancer therapy Activation of p53 by chemotherapeutic agents enhances reovirus oncolysis Sickle Cells Abolish Melanoma Tumorigenesis in Hemoglobin SS Knockin Mice and Augment the Tumoricidal Effect of Oncolytic Virus In Vivo A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy Enhanced antitumor effects of an engineered measles virus Edmonston strain expressing the wild-type N, P, L genes on human renal cell carcinoma Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice.Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway.Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human hepatoblastoma.Isolation of reovirus T3D mutants capable of infecting human tumor cells independent of junction adhesion molecule-A.Glycan engagement dictates hydrocephalus induction by serotype 1 reovirus.A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report Stabilisation of p53 enhances reovirus-induced apoptosis and virus spread through p53-dependent NF-κB activation Oncolytic virotherapy for pancreatic cancer.Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus.Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia.Antitumour responses induced by a cell-based Reovirus vaccine in murine lung and melanoma models Naturally occurring reoviruses for human cancer therapy.Deficiency of caspase 3 in tumor xenograft impairs therapeutic effect of measles virus Edmoston strain.Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia.Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses The sweet spot: defining virus-sialic acid interactions.Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors.Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy.

P2860

Q21284969-4406C21F-4E87-4A67-86E0-6DC61834F7E4 Q24567699-542D5FB3-2BD9-4960-A550-CFE1A4C114AF Q24596171-7F7896AC-7A22-4997-9D47-4D5BA262D404 Q24611483-4BC0810B-A144-46E3-97AE-A26E2C6EB2F4 Q24612603-CF6AEE67-642C-4033-8DEC-7DD481017CA7 Q24617027-24E3DDA6-4C36-4AB7-98E7-4B7A1C5F3011 Q26750568-C5356123-D608-44A8-BC05-99279C4589C0 Q26752807-A9D7A279-A711-4F0C-BF3F-9903BD5B288A Q26775033-B484C35D-26ED-4E9F-ABFC-97F8D31C4FD0 Q26797520-55BA39FB-227F-4B91-9BFB-B9A93049EAA5 Q26801501-A5883DD0-50CE-46B3-A6F2-73A7AD2E94FA Q26863779-A3AAFA27-7A24-4AC0-A346-5BC065C3DCC8 Q27690634-2702831E-CB33-4AD8-93F5-502B3FB7744F Q28069358-02E4E548-ED16-4F9B-8E5D-90A45EB45A94 Q28072347-BB2E4969-6F42-4A61-B057-E9AD17921A4A Q28485141-B37AAE75-CDE1-4A36-824F-A6E881BC5634 Q28596621-F08D7E33-7C27-48A1-B6A0-EDBCAFF0F3D4 Q33418048-9E0E0B97-D5BB-4C6B-A22A-22F250B079F0 Q33551626-59AA7A9B-2248-49D0-9330-FDC6A789375D Q33731148-B42B2274-36E2-4E11-942E-AEF128404D7D Q33815701-B8A760CA-0899-4AC1-BAA3-83F1E12CA5DF Q33924515-0B6CD1F7-7FBF-4779-B756-8CC9FD55EE85 Q34393001-2BA17AF7-ED4B-4FB9-93D2-3E868AC6FCE1 Q34421151-0B2C8953-CD3D-4828-BA90-CCBD86A56602 Q34460916-47697C57-78A0-47BB-B026-8BAFC09E1C12 Q35172332-7E2DBD74-A19A-41CA-84D9-EA0B1EE9C22C Q35224368-C75A8BEE-A7E5-4761-9BD3-869168223DBB Q35262964-827027ED-7AE7-44CE-9CDE-7E67A7126EE9 Q35590996-7D574428-B06E-4C09-A2DE-E2E3D4B459D5 Q35596563-570F3FC8-08FC-45F6-8FAB-8FC4A1ADFAF2 Q35812675-5B6AE734-D69C-44EC-AE27-F89EF0E3FA9E Q36076671-7772C2C8-15B3-47B0-91E6-8B2F30EA1BBA Q36078485-EB1C1901-8552-4DBD-B186-A3BFB736679C Q36140704-1D2B8E5B-36E9-4B39-804A-72183415AC4B Q36298608-F3295D02-35CE-4DA7-9111-7F7D8046FBC6 Q36574519-AA230DA9-C4C3-42A8-9560-84528E0FB28C Q36582819-B3575846-0E81-4B59-90C5-E1A093EE3B32 Q36685206-9F330102-C0AC-485A-AD1D-8D964E13E5A9 Q36766032-C09BA032-01F6-4053-9896-91AD3F8C0FF8 Q36766052-C35EC24A-6001-49F9-9181-DD778FA48B6F

P2860

A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer.

http://www.wikidata.org/entity/Q40405703

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

A phase I study of intravenous ...... patients with advanced cancer.

@en

A phase I study of intravenous ...... patients with advanced cancer.

@en-gb

type

label

A phase I study of intravenous ...... patients with advanced cancer.

@en

A phase I study of intravenous ...... patients with advanced cancer.

@en-gb

prefLabel

A phase I study of intravenous ...... patients with advanced cancer.

@en

A phase I study of intravenous ...... patients with advanced cancer.

@en-gb

P1433

Q40405703-B4ED7D4C-48C6-4890-BEA7-43FFC963DC6C

P1476

Q40405703-95DDD7C4-30D1-43D2-8258-E515DB10BC35

P2093

Q40405703-07BF3EFC-E55F-4298-B2BA-100356CAA69F

Q40405703-0842A3BE-FCD1-4A7A-93E2-F89DF2DA46B1

Q40405703-23A24281-926E-4EBA-A25E-44DE595ADE13

Q40405703-75CEE0E9-6C77-415A-BE90-446249A2A55D

Q40405703-9BA8F63D-02E5-4809-9A99-EE9DB63D2AB2

Q40405703-A92B88A0-CC68-4414-AB22-011F654E1C42

Q40405703-A9FD94F1-99C4-4FAF-A41D-2EBF760882CD

Q40405703-AF412966-53AE-452B-971F-B3598B0BA842

Q40405703-D285241E-C456-4438-BDB8-58B7998748CA

P304

Q40405703-21988B0D-690F-4BF5-B29B-24272C5BF6FE

P31

Q40405703-3017E7D7-D515-4659-8C21-CDA4741304EA

P356

Q40405703-F45C3958-5AF6-48FA-8D8A-36759FDB3BA1

P407

Q40405703-A1D46423-4B05-4AD2-8794-A335F5FDA20A

P433

Q40405703-FEA24718-E43E-49FD-8BE4-8E92C09D2D86

P478

Q40405703-E13372C6-153B-4B15-9572-A3A1D6A68225

P50

Q40405703-6ACD602C-5869-4A51-BEDE-672D895103AC

P577

Q40405703-AE4DA3B7-304A-4F60-A811-6347670E0D03

P698

Q40405703-06D161DF-11D6-4FE9-8A99-1F70483E38E8

P921

Q40405703-1BEE3E11-23F7-4254-96AA-A6CC2F848222

Q40405703-5728E5A1-02E2-44EE-89CF-BC6685084DA6

P356

1078-0432.CCR-08-0524

P1433

Clinical Cancer Research

P1476

A phase I study of intravenous ...... patients with advanced cancer.

@en

P2093

Christine L White

http://www.w3.org/2001/XMLSchema#string

Hardev S Pandha

http://www.w3.org/2001/XMLSchema#string

Johann S DeBono

http://www.w3.org/2001/XMLSchema#string

Katie Twigger

http://www.w3.org/2001/XMLSchema#string

Kevin J Harrington

http://www.w3.org/2001/XMLSchema#string

Laura Vidal

http://www.w3.org/2001/XMLSchema#string

Matt Coffey

http://www.w3.org/2001/XMLSchema#string

Richard G Vile

http://www.w3.org/2001/XMLSchema#string

Timothy A Yap

http://www.w3.org/2001/XMLSchema#string

P304

7127-7137

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-08-0524

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18981012

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus